CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

June 6, 2024

https://www.globenewswire.com/news-release/2024/06/06/2894657/0/en/CorMedix-Inc-Announces-CMS-Grants-Pass-Through-Status-to-Defencath.html

BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.